Biologic vs conventional DMARDs may offer cardiovascular benefits but a higher risk for infection in patients with PsA.

Review of recent advances in biomimetic drug delivery for rheumatoid arthritis, highlighting targeted nanomedicine strategies ...

Use of disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) was markedly lower among all major ...

A new nanoparticle drug has shown preclinical promise in both preventing rheumatoid arthritis and reducing painful flare-ups, offering hope for a targeted, steroid-sparing treatment that calms the ...

Patients with or without rheumatoid arthritis treated with immune checkpoint inhibitors show no significant difference in the risk for mortality, with similar causes of death, mainly due to neoplasms.

Paternal exposure to methotrexate before conception is not linked to increased risks for adverse birth outcomes, but ...

BSR’s updated csDMARD guideline introduces new evidence, whole-life-course recommendations, and risk-adaptive monitoring.

Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who cycled JAK inhibitors after inadequate response had a 38.7% remission ...

Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...

Researchers identified risks and contributing factors for preterm birth among pregnant women with psoriatic arthritis.